Please select the option that best describes you:
How would you treat an elderly, transplant-ineligible patient with recurrent DLBCL?
Would you treat differently for de novo disease vs disease arising from large cell transformation of an indolent NHL?
Answer from: Medical Oncologist at Academic Institution
There is no single standard of care in the treatment of transplant-ineligible relapsed or refractory DLBCL in the second line. Many regimens would be considered relevant considerations here, including rituximab, gemcitabine, and oxaliplatin; bendamustine and rituximab; rituximab and dose-adjusted EP...
Sign in or Register to read more